Business
Innate Pharma Reports Full Year 2025 Financial Results and Business Update
MARSEILLE, France, March 26, 2026--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its business update and consolidated financial results for the year ending December 31, 2025. The consolidated financial statements are attached to this press release.
About this update from Innate Pharma Sa Class A
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/12518dcf06103ef39f411844710c4fe1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lXRWgbbthKe1nxVX4vm7_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/12518dcf06103ef39f411844710c4fe1","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/PewukpSoJNOsTBIxykVLVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/12518dcf06103ef39f411844710c4fe1","width":1024,"height":512}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma partnering and royalty structures","length":243,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":243,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"IPH4502 (Nectin-4 ADC) shows preliminary anti-tumor activity with favorable safety profile to date; Phase 1 cohort enrichment ongoing at active dose levels","length":155,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":155,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Monalizumab PACIFIC-9 Phase 3 trial, partnered with AstraZeneca, continues to advance toward a planned H2 2026 data readout","length":123,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":123,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"IPH5201 (anti-CD39 antibody), partnered with AstraZeneca - Interim results of MATISSE Phase 2 trial in non-small cell lung cancer (NSCLC) have been selected for an oral presentation in one of the Clinical Trials Plenary Session Sessions at the AACR Annual Meeting 2026, on April 21","length":281,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":281,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Cash position of €44.8 million1 as of December 31, 2025 with an anticipated cash runway until the end of Q3 2026","length":112,"tagName":"p"...